MarketsandMarkets is proud to announce the 5th Edition Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 20-22, 2021. The expanding utilization of Real World Evidence to speed up data driven choices is further developing the clinical trial experience, but healthcare in general.
While there is extraordinary promise in utilizing Real World Data and Real World Evidence, there are some significant challenges that should be survived: potential bias of information and data sources, inadequate data sets and absence of harmonization of data between RWE data sources, access to such data, and lack of standards in evaluating the worth of Real World Evidence data. Further developing RWE is key for pharma organizations in drug development. There was big data available pre covid and now with the access data due to covid, technology enablers like AI and ML are important for big data analysis and evidence generation. Every stakeholder has faced a some impact and had to adjust.
Learn how adoption of real-world evidence can be accelerated across pharmaceutical industry
Explore capabilities of using Artificial Intelligence & Machine Learning in taming scientific research
Understand the impact of innovative real-world evidence partnerships for better data
This conference will focus on above said significant challenges and hold discussion on the best practices adopted by various stakeholders with a key takeaway being better decision making.
From Pharmaceutical and Biopharmaceutical companies
Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologists, within the following departments-